Worldwide ADNI
April 24/25, 2007
Teleconference Minutes

Attendance:
Pat Cole (Eisai/ISAB), Mike Wiener (UCSF), Giovanni Frisoni (E-ADNI), Anthony Gamst (UCSD), Takeshi Iwatsubo (J-ADNI), Chris Rowe (A-ADNI), Collin Masters (A-ADNI), Simon Lovestone (INNOMED), Tim Hsu (Eisai), John Trojanowski (UPenn), Holly Soares (Pfizer), Eric Siemers (Lilly/ISAB), David Lee (FNIH), Eve Nichols (Fidelity Foundation), Maria Carrillo (US, Alzheimer’s Assoc.),

Roll call and welcome by Maria.

US ADNI update given by Mike Weiner: 798 subjects enrolled so the study is full, there will be an over enrollment to 821 to fill PIB slots. US-ADNI is over budget and has requested ISAB funds to cover this overage. They will consider this request on April 30th. Also, a decision on the genotyping must be made and the two companies being considered are Affymetrix and Illumina. Illumina has a very strong platform but is twice the price of Affymetrix.

E-ADNI (Includes S-ADNI) update by Giovanni Frisoni. A slide was circulated to the group illustrating the status of completion. Of the 6 funded centers, 4 fully met expectations and 2 only partly. A seventh unfunded centre was added that allowed to compensate the 2 weak centres so that 52 subjects of the expected 54 have completed the study. E-ADNI Pilot has submitted a grant to the ISAB for an expansion project which will take advantage of 3 additional studies already funded in the EU. The main difference between E-ADNI and US-ADNI is the visit time points, 9 months for EU instead of 6 months. All else will be fully compatible and the ISAB will discuss this application on April 30th.

J-ADNI update given by Takeshi Iwatsubo. There will be 30 clinical sites in Japan. Funding has been granted by the Ministry of Health and Welfare, a government agency for $200,000 US over three years. This is important because it gives J-ADNI government approval. J-ADNI will apply also to NADU, another government agency, for 1.6M USD.

The J-ADNI ISAB has been organized and several industry partners are already participating. Some companies have also invested in-kind dollars summing up to ~700,000 USD per year. They have not finalized the biomarkers they will look at, but are collecting plasma and CSF. J-ADNI is planning to make all data available to the public but not in real time. There will be a very short (months) timeframe during which data will be embargoed for industry use.

A-ADNI update provided by Chris Rowe and Collin Masters. The study was launched in November and going well and according to schedule. They had a bit of an issue with storage of biofluids and a discussion took place with John Trojanowski regarding nitrogen storage vs. -80. John Trojanowski mentioned that -80 is sufficient for storage.
A-ADNI offered advice on radiolabeling and scan analysis to anyone who wants to get into PIB imaging as well as assist with the building of carbon boxes at a very reasonable price.

E-ADNI mentioned that they will share all their data with the scientific community in real-time. All PIs of the E-ADNI extension grant are in agreement that this will be the case.

Anthony Gamst was on the call to discuss compatibility with US-ADNI. J-ADNI has visited UCSD to work on sharing databases. E-ADNI has not been in touch with Anthony since the London meeting in early January, 2007. However, in the E-ADNI expansion grant there is a section which addresses that issue. A separate grant has also been submitted to the European Commission for a May2nd deadline, for the infrastructure to create a European database (3M Euros). Regardless of funding, there will be a database and Anthony Gamst will be included in these conversations, in advance of the ISAB meeting April 30th. Simon Lovestone also mentioned that the clinical data might be more laborious to conform but would not be impossible. The imaging data might require further discussions and these will be had with Anthony in the near future.

Holly Soares informed the group that the ISAB Proteomics subcommittee is looking at what biomarkers to target for plasma and have come up with a short list that was distributed via email to the group. Rules Based Medicine has thus far been the most attractive company to go with. Holly invited all Ex-ADNIs to take a look at the short list and contribute any additional analytes. Simon Lovestone from ADNEUROMED is keen on pursuing this for the ADNEUROMED study, which has a very large sample. This would be attractive to the proteomics committee because it would allow for replication in another sample. The panel will be decided upon in early June.

TC was concluded at 4:10pm CST.  
Next TC scheduled for July 24, 2007 at 3:00pm CST (July 25th in Japan and Australia).